UNSPSC 51373478: Morphine/potassium citrate/potassium guaiacolsulfonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373478 Morphine/potassium citrate/potassium guaiacolsulfonate is a Commodity code that in recent state and local procurement covers generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers and direct delivery to public health facilities. State and local issuers soliciting under this code span county health departments and multistate cooperative purchasing alliances, with purchasing driven by community health initiatives and broader pharmaceutical supply agreements that serve multiple jurisdictions and facility types simultaneously.

Recent activity appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to its Community Health Building, due July 26, 2026. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. The MMCAP RFP requires vendors to work through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and mandates cGMP certification, DSCSA compliance, $2 million network security and privacy liability coverage, and pricing submissions in CSV format with evaluations weighted 75 percent on price competitiveness.